Compare First Citizens BancShares Inc (FCNCA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Illumina, Inc. — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $24.84B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.38% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| FCNCA | ILMN | |
|---|---|---|
Market Cap | $24.84B | $28.96B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $205.10 |
52-Week Low | $1.64K | $91.00 |
Dividend Yield | 0.38% | — |
Enterprise Value | — | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,218.49, down 0.85% on the day, with strong technical indicators showing a bullish trend. The company demonstrates solid fundamentals with a P/E of 11.98, net income margin of 25.23%, and consistent earnings beats in recent quarters. Recent business developments include expansion of working capital finance services and strategic leadership appointments to drive growth across central U.S. markets.
FCNCA presents a mixed outlook with strong profitability metrics and positive earnings momentum offset by cautious analyst sentiment (81.82% hold rating). The stock trades below consensus price target of $2,310, offering potential upside, though risks include contracting net interest margins and elevated uninsured deposits at 38.3% of total deposits.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
